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What are microglial cells? 
Microglia — from micro (small) 
and glia (glue) — are the resident 
immune cells of the brain and 
constantly patrol the cerebral 
microenvironment to respond to 
pathogens and damage. These cells 
are present throughout the central 
nervous system (CNS), including the 
spinal cord, although some regions 
are more populated than others, 
with the white matter generally 
containing fewer microglia than the 
grey matter. Microglia are highly 
ramified cells and their processes 
are very active and dynamic even 
under non- pathological conditions. 
Microglia that are found close 
to blood vessels seem to lose 
their ramifications during chronic 
immune challenges, becoming more 
amoeboid in such conditions. It 
is not clear whether this process 
depends on phenotypic changes 
of the resident cells or whether 
it is a step involved during the 
differentiation of blood-derived 
cells. Amoeboid cells are also found 
throughout all stages of development 
of the CNS. Microglial cells are 
found in similar numbers to neurons, 
representing around 10–20% of all 
glial cells and ranging from 100 to 
200 billion cells depending on the 
condition (i.e., healthy, infected, 
diseased). In contrast to neurons, 
microglia can proliferate, particularly 
during infection and injury and in the 
presence of endogenously produced 
toxic proteins.
What is the origin of microglia? 
Although the exact origin of 
microglia still remains to be fully 
established, both perivascular and 
parenchymal microglial cells and 
macrophages derive from myeloid 
progenitors. It is currently believed 
that parenchymal microglia originate 
from neuroectodermal matrix cells 
and that pial macrophages or 
mesenchymal progenitors originate 
from the yolk sac, establishing 
themselves in the brain during 
the embryonic stage (Figure 1). 
However, recent data suggest the 
existence of other subpopulations 
of microglial cells, each of which may have different origins, i.e. 
those arising from the primitive 
macrophages from the yolk sac 
and those newly differentiated from 
monocytes or their progenitors. Over 
95% of all microglia are generated 
after birth and after the formation 
of the blood–brain barrier (BBB) 
and there has been an ongoing 
debate regarding the maintenance 
of the microglial population in the 
adult CNS. One hypothesis is that 
adult microglia are maintained via 
self-replication or by the division of progenitor cells already present 
in the brain. Another hypothesis 
suggests that circulating precursors 
are able to infiltrate the CNS and 
differentiate into microglial cells. 
Recent studies have demonstrated 
the capacity of bone marrow stem 
cells (BMSCs) to populate the CNS 
and differentiate into functional 
parenchymal microglia as well as 
perivascular microglia (Figure 2). It 
is important to mention that recent 
studies have raised concerns 
about such a natural infiltration of Amoeboid
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Figure 1. Phenotypes and morphologies of microglia during development and adulthood and 
under normal and inflammatory conditions. Various hypotheses for the ontogeny of microglia 
are proposed.
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about whether this mechanism is a 
physiological event in the intact CNS. 
Although the debate is still running, 
there is no doubt that BMSCs can at 
least populate the infected, injured 
and diseased brain.
Are microglial cells active during 
non-pathological conditions? 
The second debate about microglia 
relates to whether they are found 
in either a resting state or a 
vigilant state or whether they are 
only activated in the presence 
of immune stimuli (Figure 2). The 
identification of these states is, 
obviously, largely dependent on 
the tools used to evaluate such an 
activity and on the role of microglia 
under specific conditions. In vivo 
two- photon imaging in the neocortex 
generated spectacular evidence that 
microglial cells are actually highly 
active in their presumed resting 
state, continually surveying their 
microenvironment with extremely 
motile processes and ramifications. 
It seems, therefore, that these 
immune cells are never in a resting 
condition and they are dynamically 
patrolling the brain environment 
to clear it of any possible toxic 
molecules. It is interesting to 
note that BBB disruption causes 
an immediate switch in their 
behavior from patrolling the brain 
to shielding the injured site via a 
mechanism that is dependent on 
ATP/P2Y G- protein- coupled receptor 
signaling. The high basal level of 
motility of microglial processes may 
thus reflect the fluctuation of the ATP 
concentration in the surrounding 
tissue and may not necessarily 
be related to the inflammatory 
properties of microglia.
How do pathogens activate 
microglia? Microglia are isolated 
in the brain parenchyma by the 
BBB. Their direct interaction with 
pathogens and other types of 
immune cells is therefore quite 
limited, at least in the intact 
brain. The characterization of the 
Toll- like receptor (TLR) family has 
greatly contributed to a better 
understanding of the natural 
innate immune response by 
microglial cells. TLRs recognize 
pathogen-associated molecular 
patterns (PAMPs) produced by 
microorganisms, such as bacteria A B
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Figure 2. Microglia subtypes in the mouse CNS. 
(A) Resting microglia (brown cells, immunoperoxidase staining using a primary antibody directed 
against Iba1 (ionized calcium binding adapter molecule 1), a specific marker for macrophage/ 
microglia). (B) Highly ramified microglial cell (red, immunofluorescence using a primary antibody 
directed against Iba1; nuclei in blue). (C) Highly ramified microglia (immunofluorescence using 
a primary antibody directed against Iba1). (D,E) Bone-marrow-derived perivascular microglia 
(green) from chimeric mice transplanted with BMSCs expressing green fluorescent protein, GFP 
(blood vessels in red, and nuclei in blue in panel E). (F) Activated microglia expressing TLR2 
(brown ramified cells, immunoperoxidase staining using a primary antibody directed against 
Iba1; silver grains represent radioactive in situ hybridization for TLR2 mRNA). (G) Bone-marrow-
derived microglia from chimeric mice transplanted with GFP-expressing BMSCs. (H) Infiltration 
of microglial cells restricting amyloid plaques in a transgenic mouse model of Alzheimer’s dis-
ease (microglia in green; amyloid plaque in red; and nuclei in blue). Scale bar represents 20 µm in 
all panels. Images courtesy of Paul Préfontaine, Denis Soulet and Luc Vallières.and viruses. The interaction between 
lipopolysaccharide (LPS) and  
TLR4 has been widely studied in 
microglia both in vivo and in vitro.  
Systemic challenge with LPS 
triggers transcriptional activation of 
inflammatory genes in microglial cells 
throughout the brain parenchyma. 
Such widespread microglial reactivity 
to LPS is dose- and time-dependent. 
Some genes are induced very rapidly 
(e.g., IκBα, TNF-α, IL-1β, CD14), while 
others take between hours and days 
to be detected (e.g., members of the 
complement family). Direct injection 
of LPS into the CNS parenchyma also 
causes a strong, time-dependent 
transcriptional activation of 
inflammatory genes in microglial cells 
at the injection site. Such a robust 
and transient inflammatory response 
by microglia is not associated with 
neuronal damage or demyelination. 
Inhibition of these activated cells 
would seriously compromise the natural immune surveillance of the 
brain and prevent proper elimination 
of pathogenic substances in the 
cerebral microenvironment. If left 
unchecked, however, microglia may 
produce an inflammatory milieu that 
is highly detrimental.
How do injured neurons activate 
innate immunity in microglia? 
In addition to PAMPs produced 
by infectious microorganisms, a 
few host proteins are believed to 
act as endogenous ligands for 
TLRs, such as heat shock protein 
(HSP) 60, HSP70 and fibrinogen 
(all of which are able to stimulate 
proinflammatory signaling via TLR4 
and possibly TLR2). Recognition of 
these endogenous ligands is likely 
to be a natural defense mechanism 
allowing the host to mount an 
immune reaction in the presence of 
damaged tissue or severely stressed 
cells. Microglia elicit a natural innate 
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the adverse consequences of being 
transmitted to suboptimally adapted 
individuals, but they do not enjoy the 
transmission advantage associated 
with drive. Consequently, alleles present 
in individuals expressing drive may 
have lower fitness than those present 
in individuals that do not express drive. 
Thus, one way for the unlinked genes to 
fight back is to suppress drive.
X chromosome drive appears to be 
particularly common, in part because 
it is so easy to detect, being manifest 
as skewed offspring sex ratios; 
autosomal drive can only be detected 
using genetic markers. Furthermore, 
strongly driving X (or Y) chromosomes 
cannot go to fixation, as this would 
result in the loss of one sex and 
extinction of the species. These 
are systems in which frequency-
dependent mechanisms may stabilize 
the polymorphism long enough for 
suppression to evolve.
Sex chromosome drive brings about 
another cost. For simplicity, I will 
specifically consider X drive in species 
with XY males. As a driving X increases 
in frequency, the population becomes 
ever more biased towards females. 
Because every individual in a sexual 
population has one mother and one 
father, the total fitness of males equals 
the total fitness of females in terms of 
offspring production. Consequently, 
as R.A. Fisher showed, individuals of 
the rarer sex are more fit on average. 
Because the driving X chromosome 
more frequently winds up in females, 
the autosomal genes associated with 
such X chromosomes suffer reduced 
fitness. Thus, autosomal genes that 
suppress X chromosome drive are 
favored, as are resistant variants of the 
Y, the direct target of X chromosome 
drive.
X chromosome drive has been 
known since the 1920s and has been 
documented in a number of species 
of Drosophila and other flies. Until 
recently, these cases were generally 
regarded as evolutionary novelty 
items, of no great consequence for 
larger evolutionary processes. But that 
is now changing, as the consequences 
of antagonistic coevolution between 
genes that cause drive and those that 
suppress drive are coming into focus.
Nowhere is this more evident than 
in Drosophila simulans, in which 
there are both ongoing, as well as 
apparently resolved, conflicts between 
X drive and various suppressors. 
Figure 1 illustrates cytologically, in 
X chromosome drive
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In the past 10 years, the world record 
for the men’s 100 meter dash has 
declined from 9.79 to 9.74 seconds, 
the detection of such small differences 
being made possible by sophisticated 
electronic timing devices. If someone 
were to run the 100 meters in 9.73999 
seconds in the 2008 Olympics, would 
the timers be sensitive enough to show 
him to be the world’s fastest human? 
Natural selection could, as differences 
in fitness of that magnitude (10−6) 
can be detected in species with large 
effective population sizes. In this way, 
natural selection can bring about the 
evolution of exquisitely well-adapted 
creatures.
Getting back to the race, imagine 
that one of the runners somehow 
manages to get a 50-meter head 
start. With such an advantage, even 
an overweight, out of shape, or 
injured athlete could win the gold. 
An analogous situation applies in 
evolution. Mendelian segregation, 
in which the two alleles carried by a 
heterozygous individual are passed to 
equal numbers of gametes, ensures 
that alleles compete fairly and that 
they succeed (or fail) on the basis of 
their effects on survival and fertility. 
Meiotic drive — the process by which 
alleles are not represented equally in 
an individual’s gametes — subverts the 
entire process. In the best documented 
examples of drive, one allele may be 
passed on to ~100% of an organism’s 
gametes, equivalent to a runner getting 
a 50-meter head start in the 100 meter 
dash. The overrepresentation of such 
alleles in gametes can more than make 
up for any associated deficiencies 
in survival and fertility. As a result, 
these alleles — and those closely 
linked to them — can rapidly spread 
through a population, and thus actually 
cause a decline in the adaptation of 
a species to its environment. If such 
an allele drives all the way to fixation, 
the species may end up a little less 
well adapted, but there would be no 
evidence that meiotic drive was the 
cause, as drive would no longer be 
expressed.
Other genes in the genome not 
linked to those causing drive suffer 
Primerimmune response during acute injuries and this activity is believed 
to be critical for restricting damage 
and facilitating repair. Indeed, a 
timely and controlled innate immune 
response limits CNS toxicity by 
eliminating foreign materials and 
debris, thus contributing to the 
creation of an environment that is 
more permissive for regeneration  
and recovery.
How are toxic proteins cleared 
by microglia? Since microglia are 
the macrophages of the CNS, the 
promotion of an increase in their ability 
to phagocytose highly toxic proteins is 
a promising new therapeutic approach 
to prevent many diseases. Toxic 
proteins are produced in a variety of 
brain diseases, such as Alzheimer’s 
disease (b-amyloid), amyotrophic 
lateral sclerosis (superoxide  
dismutase 1), and Parkinson’s disease  
(a-synuclein). Microglia are recruited 
in such conditions, but they are not 
necessarily efficient at phagocytosis 
and removal of these toxic proteins 
from the extracellular environment. 
In the case of Alzheimer’s disease, 
increasing the infiltration of blood-
derived microglial cells seems likely 
to be a useful therapeutic approach, 
since these cells are able to eliminate 
or prevent the formation of b-amyloid 
deposits. Immunization against 
b- amyloid stimulates the recruitment 
of bone-marrow-derived microglia 
and improves both the clearance of 
the protein and cognitive function. 
It is tempting to propose that such 
a strategy could also be efficient in 
clearing secreted and toxic proteins 
involved in many other diseases that 
affect the CNS.
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